CytoDyn Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYDY Over the counter 8731 https://www.cytodyn.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CytoDyn Inc

Ousted CEO Pourhassan sues CytoDyn to cover his attorney's fees - Jan 24th, 2023 8:32 pm
Kazem Kazempour, CEO of Germantown biotech firm Amarex, charged with securities fraud - Dec 23rd, 2022 1:23 pm
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO - Dec 23rd, 2022 1:00 pm
After ex-CEO Pourhassan's indictment, what's left of CytoDyn? - Dec 21st, 2022 9:59 pm
Two Biotech CEOs Indicted on Securities Fraud Charges - Dec 20th, 2022 10:36 pm
Ousted CytoDyn CEO Pourhassan indicted for alleged securities fraud - Dec 20th, 2022 8:19 pm
CytoDyn to Host R&D Update on Wednesday, December 7, 2022 - Nov 22nd, 2022 1:30 pm
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues - Oct 28th, 2022 9:15 pm
CytoDyn Announces Appointment of Additional Directors with Industry Experience - Oct 20th, 2022 12:30 pm
CytoDyn to Hold Webcast to Provide a Quarterly Company Update - Sep 19th, 2022 12:30 pm
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President - Jul 13th, 2022 12:30 pm
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab - Jul 11th, 2022 12:30 pm
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer - May 23rd, 2022 12:30 pm
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor - May 13th, 2022 12:00 pm
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species” - Apr 12th, 2022 12:30 pm
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program - Mar 30th, 2022 9:00 pm
CytoDyn to Hold Webcast to Provide Company Update - Mar 30th, 2022 12:30 pm
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS - Mar 1st, 2022 9:05 pm
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences - Feb 28th, 2022 9:15 pm